Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 341-345

  Facciolà, Gabriella ^a   Avenoso, Angela ^a   Scordo, Maria G ^a   Madia, Aldo G ^b   Ventimiglia, Andrea ^c   Perucca, Emilio ^d   Spina, Edoardo ^a,b,e  

^a UNIVERSITY OF MESSINA   (Italy)

^b ASL 5   (Italy)

^c Villa dei Gerani Clinic   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

Clozapine; Clozapine N oxide; Drug interaction; Norclozapine; Valproic acid

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; NORCLOZAPINE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; STEADY STATE;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; SCHIZOPHRENIA; VALPROIC ACID;

EID: 0033045133     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00017     Document Type: Article

References (25)

1. Baldessarini RJ, Frankenburg FR. Clozapine, a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
2. Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995;4:370-400.
3. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
4. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-71.
5. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161-76.
6. Haring C, Fleishacker WW, Schett P. et al. Influence of patient-related variables on clozapine plasma concentrations. Am J Psychiatry 1990;147:1471-5.
7. Edge SC, Markovitz JS, DeVane CL. Clozapine drug-drug interactions: a review of the literature. Hum Psychopharmacol 1997; 12:5-20.
8. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy. Clin Pharmacokinet 1997;32:93-100.
9. Balfour JA, Bryson HM. Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994;2:144-73.
10. Kando JC, Tohen M, Castillo J. Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994;55:255-7.
11. Wilson W. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995;37:132-3.
12. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-8.
13. Longo LP, Salzman C. Valproic acid effects on serum concentration of clozapine and norclozapine [letter]. Am J Psychiatry 1995; 152:650.
14. Centorrino F, Baldessarini RJ, Kando J. et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
15. Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am J Med 1988;84:29-33.
16. Avenoso A, Facciola G, Campo GM, Fazio A, Spina E. Determination of clozapine, N-desmethyldozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chro-matography with ultraviolety detection. J Chromatogr B Biomed Appl 1998;714:299-308.
17. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
18. Tiihonen M, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28;26-8.
19. Miller D. Effect of phenytoin on plasma clozapine concentration in two patients. J Clin Psychiatry 1991;52:23-5.
20. Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998;20:628-30.
21. Pirmohamed M, Williams D, Madden S, et al. Metabolism and biactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
22. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
23. Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum B, eds. Antiepileptic Drugs, IV Edition. New York: Raven Press, 1995; 31-50.
24. Costello L, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995;15:139-40.
25. Fuchs C. Clozapine treatment of bipolar disorder in a young adolescent. J Am Acad Child Adolesc Psychiatry 1994;33:1299-302.